Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Topical minoxidil and anthralin work for patchy alopecia areata but not for alopecia totalis/universalis.

This study found that 1% topical minoxidil significantly promoted hair regrowth in patients with alopecia areata, though it was less effective or ineffective in more severe forms like alopecia totalis and universalis.

This review discusses the associations between nonscarring alopecia and conditions like vitiligo and autoimmune reactions, but reports no new clinical results.

This letter discusses prior findings on prednisone for alopecia areata, agreeing that systemic steroids usually do not change the disease course but contesting that most patients have a poor prognosis.

This abstract provides no clinical results; it describes terms and navigation options for the JAMA network and its publications.

This article discusses prevalent skin diseases in children, including alopecia areata, and reports no new clinical results; it outlines conditions and treatment options without presenting original data.

This study found that women with androgenetic alopecia or alopecia areata have significantly lower serum ferritin levels than those without hair loss, suggesting a potential link between these types of alopecia and decreased iron stores.

The 308-nm excimer laser helps hair regrowth in some alopecia areata cases but not all.

This study found that the 308-nm Excimer laser was effective and safe for treating patchy alopecia areata in children, with hair regrowth observed in 60% of treated scalp patches.

This letter to the editor discusses a potential link between new onset alopecia areata and SARS-CoV-2 infection, but reports no new clinical results.

This study reported that 45.5% of patients with beard alopecia areata progressed to scalp alopecia areata within at least 12 months, with most cases occurring during the first year.

This article reviews side effects and relapse rates of various systemic treatments for severe alopecia areata, reporting no new clinical findings.

This study found that hyperpigmentation following contact immunotherapy for severe alopecia areata may indicate poor treatment responsiveness and aligns with characteristics of pigmented contact dermatitis.

This report describes a case of twins with alopecia areata totalis who did not respond to corticosteroids but showed significant hair growth with platelet rich plasma injections, suggesting PRP's potential as an alternative treatment.

This case study suggests that autoimmunity involving cytotoxic CD8+ T cells may link alopecia areata and human T-cell lymphotropic virus-1-associated myelopathy in adult T-cell leukemia/lymphoma patients.

This study observed a significant 207.62% increase in hospitalization rates for alopecia areata after the COVID-19 pandemic, with notable shifts in disease subtypes and patient demographics, suggesting a potential link between the pandemic and changes in the disease's course.

This study highlights the use of dermatoscopy as a valuable tool for diagnosing and monitoring alopecia areata, noting that specific hair shaft alterations such as exclamation-mark hairs and black dots are indicators of active disease, while vellus hairs signal early regrowth.

The authors concluded that alopecia areata incognita, mainly affecting young females, generally has a more favorable prognosis than other types of alopecia areata.

This study observed that recurrent alopecia areata patients with salmon patches on the nape often had severe disease, particularly alopecia areata ophiasis, which was more common in females.

This case report describes two twins with alopecia areata totalis who experienced noticeable hair regrowth following platelet rich plasma injections, suggesting PRP as a potential treatment alternative.

This case report highlights that new nonscarring alopecia after transplantation may indicate chronic graft-vs-host disease, with dermatologists playing a key role in diagnosis and treatment.

This study found that a significant portion of alopecia areata patients achieved at least partial hair regrowth with diphenylcyclopropenon therapy, which was more effective in certain subtypes and disease durations.

This article discusses treatments for alopecia areata totalis and reports no new results from prednisolone local injections; previous therapies included cortisone, ultraviolet treatment, and others without success.

This study found that phototherapy was more effective for patients with the multiple or totalis types of alopecia areata, with whole-body phototherapy potentially benefiting those with refractory universalis type.

In this study, treatment of alopecia areata, totalis, and universalis with methyl prednisolone and ACTH injections resulted in complete regrowth in 62% of male and 58% of female patients.

This study found that among Chinese patients with alopecia areata, those with alopecia totalis or universalis had an earlier onset, longer disease duration, and more severe quality of life impact than those with patchy alopecia.

In this case report, individualized homeopathic treatment based on symptom totality led to anxiety reduction, halted lesion progression, and complete cosmetic recovery in a 30-year-old male with alopecia areata barbae, highlighting a potential area for further controlled studies.

The ISHRS 2007 Practice Census survey reported a 34% increase in global hair restoration procedures, totaling approximately 225,800 in 2006.

This study found that immunotherapy with DNCB or DPCP showed better therapeutic effects than intralesional triamcinolone acetonide for patients with bald areas greater than 50 cm², including alopecia totalis and universalis.

In this study, daily treatment with ritlecitinib for up to 24 months led to significant reductions in high-severity alopecia areata SALT scores among patients aged ≥12 years, including those with severe forms such as alopecia totalis and universalis.